MEDCAPTAIN

2041
6.0352.58% ( -0.160 )
Delay Closed: Nov 16, 16:08:11

Overview

MEDCAPTAIN (2041)

Medcaptain Medical Technology Co., Ltd. manufactures integrated perioperative medical devices in China, Europe, Asia, the Middle East, Africa, North America, an...

Open
6.050
High
6.080
Low
5.900
Prev. Close
6.195
Volume
135.90K
Turnover
809.66K
Avg Price
5.958
Bid/Ask Ratio
97.24%
Amplitude
2.91%
52wk High
10.900
Volume Ratio
0.00
Turnover Ratio
0.03%
52wk Low
5.850
HK Mkt Cap
2.89B
Market CapHKD
3.25B
P/ETTM
297.13
P/EDynamic
1,753.61
P/EStatic
--
EPSTTM
0.0203
EPSDynamic
0.0034
EPSStatic
--
BVPS
4.11
P/B
1.47
HK Shares
479.22M
Dividend YieldTTM
--
DividendTTM
--
Shares
538.63M
Min lot size
100
Currency
HKD

MEDCAPTAIN Analyst Rating

View more

Forecast & Rating

Oct 14, 2026
Price forecast
HK$11.0182.36%
Forecast & RatingBuy
1analysts
  • Strong buy0.00%
  • Buy100.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 10

    Medcaptain staged a late-session recovery after touching a 52-week low of HK$5.85 on 8 November: it eased to HK$6.00 in the morning session, climbed to HK$6.54 in the afternoon, and closed at HK$6.41, up 7.55%, on 515,000 shares and HK$3.26 million turnover, a thin 0.11% turnover rate. The rebound contrasts with the earnings profile: Q2 2026 revenue rose 16.64% year on year to HK$551.9 million, yet net profit fell 88.3% to HK$4.51 million and operating income dropped 78.4% to HK$9.79 million, while Q1 booked a HK$3.52 million net loss; the latest disclosures showed Q3 adjusted EBITA and sales up 30% and 13% respectively, and Morgan Stanley initiated coverage. The stock remains below its MA60 of HK$7.198, down 27.16% year to date and 41.19% below its HK$10.90 52-week high, at a PE of 315.6x and PB of 1.56x. Though a HK$3.45 billion market cap and light turnover leave daily swings easily amplified.

  2. Nov, 6

    Medcaptain (2041.HK) closed at HK$5.995, down 2.68%, after opening flat at HK$6.16 and sliding to a 14:08 low of HK$5.85, a fresh 52-week low, before a small late recovery; volume was only 154,200 shares worth HK$0.91 million at a 0.03% turnover rate, so thin liquidity rather than fresh news drove the tape. Fundamentals cut both ways: Q3 adjusted EBITA rose 30% and sales 13%, and Q2 revenue reached HK$551.9 million, up 16.6% year on year, yet net profit was just HK$4.51 million, down 88.3%, with operating profit off 78.4% — revenue growth has not converted into earnings. Morgan Stanley initiated coverage with an Overweight rating on the platform model, but the shares still sit below the MA20 of HK$6.35 and MA60 of HK$7.24, down 31.9% year to date and 45% below the 52-week high of HK$10.9. A cooling Hong Kong IPO market and rising break-issue rates weigh on the recently listed stock.

  3. Oct, 26

    Medcaptain (02041.HK) traced a dip-and-rebound session: it slid to 5.955 in the morning, rallied to an intraday 6.460 in the afternoon and settled at 6.440 against a 6.290 prior close, up about 2.4%, driven by Q3 adjusted EBITA growth of 30% with sales up 13% and Morgan Stanley's initiation at Overweight. That contrasts with thin profitability, as Q2 revenue of HK$551.9m rose 16.6% year on year but net profit of HK$4.51m fell 88.3%, leaving EPS at HK$0.009 and the net margin at 0.82%. Price position stays weak: down 28.4% year to date, 42.2% below the HK$10.90 52-week high, beneath the MA20 of 6.841 and MA60 of 7.526, and only 5.9% above the 5.95 52-week low. Though cooling Hong Kong IPO demand, soft retail subscription and a reported 52-week low suggest post-listing liquidity pressure lingers.

  4. Oct, 16

    The Shenzhen-based medical device maker (2041.HK) traced a spike-and-fade session: it opened at HK$6.695, tagged HK$7.000 at 09:41 BJ before momentum stalled, ground lower through the afternoon to HK$6.500 at 15:43 BJ and closed at HK$6.580, the bottom of the day's range and roughly 6.0% below the intraday peak. Volume was thin at 82,400 shares worth HK$554,929, with the HK$6.735 average price sitting above the close, pointing to late-session selling pressure. Having listed on the HKEX only on 7 September 2026, the company is under six weeks into trading, so YTD performance, 52-week high/low and moving-average reference points are not yet available; price is instead shaped by a small free float and light turnover. While the very low single-day volume limits how much weight the move carries.

  5. Oct, 15

    MEDCAPTAIN fell 5.44% to HK$6.695 after spiking to HK$7.425 in early trade and sliding through the session, tagging its intraday low of HK$6.695 at 15:57 BJ, close to the HK$6.075 52-week low set on Oct 12. The move tracks a Hong Kong healthcare IPO glut: weekly recaps flagged a 5.27% weekly decline and repeated post-listing lows, while over 10 A-share issuers have postponed Hong Kong listings and several healthcare debutants broke issue price. Fundamentals show a widening gap, as Q2 revenue of HK$551.9mn rose 16.64% yoy but net profit of only HK$4.51mn fell 88.29%, with EPS at HK$0.0090 and operating profit down 78.38%, while Q1 remained a HK$3.52mn loss, leaving PE at 329.6x and PB at 1.63x. The stock is down 23.92% YTD, 38.58% below its HK$10.9 52-week high and under its MA20 of HK$7.388 and MA60 of HK$7.778, with market cap of HK$3.61bn. Revenue growth, though, remains double-digit.

News